Real-Time Continuous Glucose Monitor (RTCGM) Use Associated with Decreased Diabetes Medical Costs for Patients with Type 2 Diabetes (T2D)

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

• This retrospective analysis aimed to evaluate the impact of real-time continuous glucose monitoring (rtCGM) on medical costs in 571 people with type 2 diabetes.
• rtCGM use in real-world settings was associated with reduction in diabetes-related medical costs from $1,680 to $1,256 per person per month.
• The reductions were driven by reductions in diabetes-related medical care costs.
• Increased access to rtCGM may help reduce costs of care.